NL980012I2 - Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen. - Google Patents

Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.

Info

Publication number
NL980012I2
NL980012I2 NL980012C NL980012C NL980012I2 NL 980012 I2 NL980012 I2 NL 980012I2 NL 980012 C NL980012 C NL 980012C NL 980012 C NL980012 C NL 980012C NL 980012 I2 NL980012 I2 NL 980012I2
Authority
NL
Netherlands
Prior art keywords
preparation
pharmaceutical compositions
mometasone furoate
furoate monohydrate
monohydrate
Prior art date
Application number
NL980012C
Other languages
English (en)
Other versions
NL980012I1 (nl
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24320279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL980012(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NL980012I1 publication Critical patent/NL980012I1/nl
Publication of NL980012I2 publication Critical patent/NL980012I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
NL980012C 1990-09-10 1998-03-12 Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen. NL980012I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58023990A 1990-09-10 1990-09-10
PCT/US1991/006249 WO1992004365A1 (en) 1990-09-10 1991-09-06 Mometasone furoate monohydrate, process for making same and pharmaceutical compositions

Publications (2)

Publication Number Publication Date
NL980012I1 NL980012I1 (nl) 1998-05-06
NL980012I2 true NL980012I2 (nl) 2004-11-01

Family

ID=24320279

Family Applications (1)

Application Number Title Priority Date Filing Date
NL980012C NL980012I2 (nl) 1990-09-10 1998-03-12 Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.

Country Status (35)

Country Link
US (1) US6180781B1 (nl)
EP (1) EP0548114B1 (nl)
JP (1) JPH0725789B2 (nl)
KR (1) KR960013445B1 (nl)
CN (1) CN1030920C (nl)
AT (1) ATE113604T1 (nl)
AU (1) AU663471B2 (nl)
BG (1) BG60755B2 (nl)
CA (1) CA2091360C (nl)
CZ (1) CZ281318B6 (nl)
DE (2) DE69104991T2 (nl)
DK (1) DK0548114T5 (nl)
EE (1) EE02962B1 (nl)
ES (1) ES2065701T3 (nl)
FI (1) FI111078B (nl)
HK (1) HK185996A (nl)
HR (1) HRP920383B1 (nl)
HU (1) HU213401B (nl)
IE (1) IE67056B1 (nl)
IL (1) IL99437A (nl)
LU (1) LU90366I2 (nl)
MX (2) MX9203396A (nl)
MY (1) MY106644A (nl)
NL (1) NL980012I2 (nl)
NO (1) NO300548B1 (nl)
NZ (1) NZ239711A (nl)
OA (1) OA09772A (nl)
PH (1) PH30443A (nl)
PL (1) PL165803B1 (nl)
PT (1) PT98905B (nl)
SI (1) SI9111497A (nl)
TW (2) TW272195B (nl)
WO (1) WO1992004365A1 (nl)
YU (1) YU48666B (nl)
ZA (1) ZA917148B (nl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE113604T1 (de) * 1990-09-10 1994-11-15 Schering Corp Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
CN1059476C (zh) * 1996-08-21 2000-12-13 邓维鹏 金黄色铝合金硒盐电解着色方法
AU9674398A (en) * 1997-10-09 1999-05-03 Schering Corporation Mometasone furoate suspensions for nebulization
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
AU2004268847A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-IV
WO2005051931A2 (en) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
EP1948167A1 (en) * 2005-10-19 2008-07-30 Ranbaxy Laboratories, Ltd. Compositions of phosphodiesterase type iv inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CN100389121C (zh) * 2005-12-09 2008-05-21 天津药业集团有限公司 糠酸莫美他松中间体21-羟的制备方法
CN100436473C (zh) * 2005-12-09 2008-11-26 天津药业集团有限公司 糠酸莫美他松中间体21-酯及制法
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
EA200900472A1 (ru) * 2006-09-22 2009-10-30 Ранбакси Лабораторис Лимитед Ингибиторы фосфодиэстеразы iv типа
US20100029728A1 (en) * 2006-09-22 2010-02-04 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
EP2124943A1 (en) * 2007-03-14 2009-12-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
US8420666B2 (en) 2007-03-14 2013-04-16 Ranbaxy Laboratories Limited Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
TWI792140B (zh) 2009-05-29 2023-02-11 美商沛爾醫療股份有限公司 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
CN107260671B (zh) * 2016-04-08 2021-03-26 天津金耀集团有限公司 一种糠酸莫米松混悬鼻喷剂组合物
CN107266518B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种糠酸莫米松晶型及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3260474D1 (en) * 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4783444A (en) 1984-09-17 1988-11-08 Schering Corporation Antiglaucoma compositions and methods
US4808610A (en) * 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) * 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
ATE113604T1 (de) * 1990-09-10 1994-11-15 Schering Corp Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.

Also Published As

Publication number Publication date
DK0548114T5 (da) 1995-01-30
IE67056B1 (en) 1996-02-21
HRP920383B1 (en) 2000-04-30
IE913155A1 (en) 1992-03-11
NL980012I1 (nl) 1998-05-06
NO300548B1 (no) 1997-06-16
US6180781B1 (en) 2001-01-30
NZ239711A (en) 1992-09-25
IL99437A (en) 1995-05-29
CZ38393A3 (en) 1994-01-19
CZ281318B6 (cs) 1996-08-14
OA09772A (en) 1993-11-30
PT98905B (pt) 1998-08-31
MX9100990A (es) 1992-05-04
EP0548114A1 (en) 1993-06-30
PT98905A (pt) 1992-09-30
AU663471B2 (en) 1995-10-12
HU213401B (en) 1997-06-30
FI931031A (fi) 1993-03-09
ZA917148B (en) 1992-08-26
ATE113604T1 (de) 1994-11-15
SI9111497A (sl) 1998-04-30
NO930693D0 (no) 1993-02-26
JPH0725789B2 (ja) 1995-03-22
MX9203396A (es) 1992-07-31
BG60755B2 (bg) 1996-02-29
IL99437A0 (en) 1992-08-18
CA2091360A1 (en) 1992-03-11
TW229208B (nl) 1994-09-01
FI931031A0 (fi) 1993-03-09
LU90366I2 (fr) 1999-05-05
HK185996A (en) 1996-10-11
DE69104991T2 (de) 1995-04-20
HUT64361A (en) 1993-12-28
ES2065701T3 (es) 1995-02-16
HU9300685D0 (en) 1993-06-28
NO930693L (no) 1993-02-26
DE19875032I2 (de) 2007-04-19
JPH05506667A (ja) 1993-09-30
CN1059911A (zh) 1992-04-01
TW272195B (nl) 1996-03-11
EE02962B1 (et) 1997-02-17
PH30443A (en) 1997-05-09
YU149791A (sh) 1994-01-20
MY106644A (en) 1995-07-31
AU8497491A (en) 1992-03-30
HRP920383A2 (en) 1998-06-30
DE69104991D1 (de) 1994-12-08
FI111078B (fi) 2003-05-30
EP0548114B1 (en) 1994-11-02
KR960013445B1 (ko) 1996-10-05
CN1030920C (zh) 1996-02-07
CA2091360C (en) 1997-04-08
YU48666B (sh) 1999-06-15
PL165803B1 (pl) 1995-02-28
WO1992004365A1 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
NL980012I2 (nl) Mometasonfuroaat-monohydraat, werkwijze om zulks te bereiden en farmaceutische samenstellingen.
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
UA34428C2 (uk) Заміщені фенілімідазолідини, спосіб їх одержання, фармацевтична композиція, проміжні сполуки
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
GB8823567D0 (en) 4h-1-benzopyran-4-one derivative/its salt & process for producing same
IL58782A0 (en) Hydroxypropyl-triazole compounds,their production and pharmaceutical compositions containing them
IT1190824B (it) Composizione farmaceutica contenente 24,25-diidrossicolecalciferolo come ingrediente attivo
GR1001597B (el) Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών.
FI954931A0 (fi) Uusia piperidinyylitioindolin johdannaisia, niiden valmistusmenetelmä, niitä sisältäviä farmaseuttisia koostumuksia, jotka ovat käyttökelpoisia erityisesti kivun lievittäjinä
IT7927243A0 (it) Per la loro preparazione e composti triazinonici, procedimenti composizioni farmaceutiche che licontengono.
ES8504166A1 (es) Un metodo de preparar derivados de 6,11-dihidrodibenz(b,e) oxepina.
ES474052A1 (es) Procedimiento para la obtencion de 1,4-dihidropiridazinas 1-n-sustituidas.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
IT8421627A0 (it) Composizione farmaceutica contenente come ingrediente attivo 24,25-diidrossicolecalciferolo.
IT8220979A0 (it) Derivato della propionilglicina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono come principio attivo.